Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MLH1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

MLH1 mutation	Gastric Cancer	MLH1 mutation	Gastric Cancer	tremelimumab-actl Sensitive: C2 – Inclusion Criteria tremelimumab-actl Sensitive : C2	tremelimumab-actl Sensitive: C2 – Inclusion Criteria tremelimumab-actl Sensitive : C2
MLH1 mutation	Gastric Cancer	MLH1 mutation	Gastric Cancer	durvalumab + tremelimumab-actl Sensitive: C2 – Inclusion Criteria durvalumab + tremelimumab-actl Sensitive : C2	durvalumab + tremelimumab-actl Sensitive: C2 – Inclusion Criteria durvalumab + tremelimumab-actl Sensitive : C2
MLH1 mutation	Prostate Cancer	MLH1 mutation	Prostate Cancer	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2
MLH1 mutation	HER2 Positive Breast Cancer	MLH1 mutation	HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3
MLH1 mutation	Urothelial Cancer	MLH1 mutation	Urothelial Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
MLH1 mutation	Urothelial Cancer	MLH1 mutation	Urothelial Cancer	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4